LENSAR (LNSR) AI Stock Analysis

• Market Cap: $144.89M
• Dividend Yield: N/A
• Average Volume (3M): 65.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: 29.34%
• EPS Growth: -283.53%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.15
• Shares Outstanding: 11,934,784
• 10 Day Avg. Volume: 67,224
• 30 Day Avg. Volume: 65,403
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 2.62
• Enterprise Value/Gross Profit: 5.56
• Enterprise Value/Ebitda: -12.71
• 1Y Price Target: $11.50
• Price Target Upside: -4.64% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $11.50 ▼(-4.64% Downside)

LENSAR's overall stock score reflects significant financial challenges, with persistent losses and a weak balance sheet. Technical analysis indicates bearish trends, and valuation metrics are unfavorable due to negative earnings. The absence of earnings call insights and corporate events limits the analysis to financial and technical factors.

Positive Factors

Revenue Growth

LENSAR's significant revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

Cash Flow Efficiency

Positive free cash flow growth suggests effective cash management, providing resources for reinvestment and reducing financial strain.

Market Position

Specialization in cataract surgery technology positions LENSAR as a leader in a niche market, enhancing competitive advantage and customer loyalty.

Negative Factors

Balance Sheet Health

A concerning balance sheet with negative equity suggests potential solvency issues, limiting financial flexibility and increasing risk.

Profitability Challenges

Persistent net losses and negative margins highlight ongoing operational challenges, impacting long-term profitability and sustainability.

Operating Cash Flow

Negative operating cash flow indicates challenges in generating sufficient cash from core operations, potentially straining liquidity.

LENSAR Business Overview & Revenue Model

Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

How the Company Makes Money

LENSAR generates revenue through the sale of its proprietary LENSAR Laser Systems and the associated consumables used during cataract surgeries, such as disposable tips and patient-specific software. The company also earns income from service contracts and maintenance agreements for its equipment. Significant partnerships with ophthalmic surgery centers and hospitals play a crucial role in expanding its market reach and driving sales. Additionally, LENSAR may benefit from reimbursements from insurance providers for procedures performed using its technology, enhancing its overall revenue potential.

LENSAR Financial Statement Overview

Summary

LENSAR is experiencing revenue growth but faces significant financial challenges, including persistent losses, negative equity, and cash flow issues. These factors indicate a need for strategic improvements in profitability and balance sheet management.

Income Statement

LENSAR has demonstrated revenue growth, with a TTM increase of approximately 6.68% compared to the previous year. However, the company continues to face profitability challenges, as reflected in negative net profit and EBIT margins, standing at -99.17% and -16.49% respectively for the TTM. The gross profit margin is 47.45%, showing some strength in core operations, but the persistent losses are concerning.

Balance Sheet

The company's financial stability is concerning with a negative stockholders' equity of -$22.14 million, indicating insolvency risk. The debt-to-equity ratio is negative due to negative equity, complicating leverage analysis. The equity ratio is also negative. These factors highlight financial instability, despite manageable total liabilities relative to assets.

Cash Flow

LENSAR's cash flow situation is challenging, with negative free cash flow of -$4.05 million in the TTM and a negative free cash flow growth rate, suggesting cash generation issues. The operating cash flow to net income ratio is 0.069, indicating poor cash conversion of net losses. Continued reliance on financing activities is evident from cash inflows in this segment.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.36M	53.49M	42.16M	35.36M	34.46M	26.38M
Gross Profit	27.52M	25.85M	21.11M	19.95M	17.83M	14.07M
EBITDA	-12.04M	-27.47M	-8.71M	-16.77M	-18.10M	-15.36M
Net Income	-49.31M	-31.40M	-14.38M	-19.91M	-19.65M	-19.77M
Balance Sheet
Total Assets	70.41M	66.30M	69.58M	55.84M	66.47M	79.12M
Cash, Cash Equivalents and Short-Term Investments	20.31M	22.45M	24.06M	14.67M	31.64M	40.60M
Total Debt	2.33M	2.61M	2.31M	2.80M	3.31M	3.81M
Total Liabilities	79.68M	47.65M	22.41M	13.86M	11.59M	11.91M
Stockholders Equity	-9.27M	4.86M	47.18M	41.98M	54.88M	67.21M
Cash Flow
Free Cash Flow	-5.23M	-2.43M	-9.89M	-14.97M	-9.32M	-14.16M
Operating Cash Flow	-5.13M	-2.27M	-9.66M	-14.86M	-8.97M	-13.79M
Investing Cash Flow	-5.87M	-2.16M	-4.16M	-115.00K	-354.00K	-326.00K
Financing Cash Flow	9.86M	78.00K	19.76M	-1.99M	361.00K	50.00M

LENSAR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNSR, the sentiment is Negative. The current price of 12.06 is below the 20-day moving average (MA) of 12.30, below the 50-day MA of 12.66, and below the 200-day MA of 12.16, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 43.57 is Neutral, neither overbought nor oversold. The STOCH value of 46.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LNSR.

LENSAR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	70 Outperform	199.04M	27.42	―	―	16.97%	48.56%
CVRX	48 Neutral	195.09M	-3.48	-90.19%	―	23.11%	18.06%
SGHT	47 Neutral	185.38M	-3.58	-58.85%	―	-3.89%	9.68%
CTSO	46 Neutral	59.81M	-5.08	-84.14%	―	-7.81%	65.39%
MYO	44 Neutral	39.31M	-4.01	-25.02%	―	93.07%	13.25%
LNSR	41 Neutral	$144.89M	―	-350.22%	―	29.34%	-283.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

LENSAR Corporate Events

LENSAR Stockholders Approve Merger with Alcon Research

On July 2, 2025, LENSAR, Inc. held a virtual special meeting where stockholders voted on proposals related to a merger agreement with Alcon Research, LLC. The merger proposal, along with a compensation proposal for executives related to the merger, was approved by the requisite vote. The adjournment proposal was deemed unnecessary as there was a quorum present and sufficient proxies to approve the merger proposal.

The most recent analyst rating on (LNSR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.